Work

SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study

Year: 2023
Type: conference-abstract
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4382810747
Cites:
Cited by: 2
Related to: 10